
New maternal vaccine options could offer extra protection in upcoming seasons.

New maternal vaccine options could offer extra protection in upcoming seasons.

Exposure to a common seasonal coronavirus stimulates a memory T cell response that protects children against COVID-19. However, this immune response peaks at age 6.

If approved by the FDA, this 5-in-1 investigational candidate could provide the broadest meningococcal serogroup coverage.

At the 44th National Association of Pediatric Nurse Practitioners Conference, data was presented on the effectiveness of vaccines and antivirals in preventing life threatening conditions.

Assessing your knowledge of and performance on preventable diseases.

The Omicron variant caused the most symptoms in pediatric patients. However, there were no differences in adverse outcomes by COVID-19 variant.

Children were hospitalized the most during the Omicron variant, but disease outcomes were the least severe during this variant period.

The federal agency set a Prescription Drug User Fee Act (PDUFA) action date of August 2023.

In a recent analysis, worse maternal and neonatal outcomes were found when mothers were infected with COVID-19 close to delivery.

A recent grant awarded to Ann & Robert H. Lurie Children's Hospital of Chicago will look at the severity score of emergency department (ED)-based pediatric community-acquired pneumonia.

To address the increased demand for fever-reducing medications, the FDA has updated its compounding guidelines for licensed pharmacies, hospitals, and health systems.

In a recent study, children aged under 5 years with COVID-19 more often presented with severe illness when comorbid with another respiratory illness.

More contagious but less severe, XBB takes over as dominant Omicron strain of COVID-19

When analyzing morbidity data from 2021, investigators found that COVID-19 was among the 10 leading causes of death among children and young people.

Worst of ‘tripledemic’ may be over.

New maternal vaccine options could offer extra protection in upcoming seasons.

The US Food Administration has agreed to review an application for nirsevimab (Beyfortus; AstraZeneca and Sanofi) to protect infants against RSV.

The results show similar rates o colonized C difficile among pediatric patients and adult patients with cystic fibrosis.

Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, editor-in-chief of Contemporary Pediatrics, talks about the most significant moments in children’s health in 2022; what the tridemic really means for pediatric health care providers; and what we have to look forward to in 2023 when it comes to new vaccines and medications.

Alok Patel, MD, shares what pediatric health care providers should know about a concerning new strain of group A streptococcus.

New surveillance data from the 2021-22 influenza show the impact of coinfection among younger patients.

Steven Selbst, MD, pediatric emergency medicine physician at Nemours Children's Health, discusses the surge of RSV cases and hospitalizations this season.

In a recent statement, the American Academy of Pediatrics discussed how patients with respiratory infections can be managed, along with guidance on RSV treatment.

Tell your patients to get their annual flu vaccines for best protection against illness.

In a recent study, investigators found that life-threatening neurologic conditions from severe acute COVID-19 were more frequent in 2021 than 2020.